CSIMarket
 


Longeveron Inc   (LGVN)
Other Ticker:  
 

Longeveron Inc 's Working Capital Ratio

LGVN's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




LGVN Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 164.98 % 117.82 % - - -
Y / Y Current Assets Change 18.16 % 27.71 % - - -
Working Capital Ratio MRQ 6.25 7.8 13.28 16.3 14.03
Overall Ranking # # # # #
Seq. Current Liabilities Change 2.68 % 50.75 % 10.55 % 54.85 % -15.59 %
Seq. Current Assets Change -17.71 % -11.39 % -9.93 % 79.91 % -11.06 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 6.25 above Longeveron Inc average.

Within Major Pharmaceutical Preparations industry Longeveron Inc booked the highest Working Capital Ratio than Longeveron Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is LGVN most successful ?
Working Capital Ratio LGVN on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Longeveron Inc 's Current Liabilities $ 4 Millions Visit LGVN's Balance sheet
Longeveron Inc 's Current Assets $ 23 Millions Visit LGVN's Balance sheet
Source of LGVN's Sales Visit LGVN's Sales by Geography


Cumulative Longeveron Inc 's Working Capital Ratio

LGVN's Working Capital Ratio for the trailling 12 Months

LGVN Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 164.98 % 117.82 % - - -
Y / Y Current Assets TTM Growth 18.16 % 27.71 % - - -
Working Capital Ratio TTM 9.97 12.01 14.28 14.74 13.64
Total Ranking TTM # 376 # 480 # 455 # 279 # 454
Seq. Current Liabilities TTM Growth 2.68 % 50.75 % 10.55 % 54.85 % -15.59 %
Seq. Current Assets TTM Growth -17.71 % -11.39 % -9.93 % 79.91 % -11.06 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $3.72 millions, average cumulative Working Capital Ratio decreased to 9.97 below the Longeveron Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 148 other companies have achieved higher Working Capital Ratio than Longeveron Inc . While overall ranking remained unchanged compare to previous quarter at no. 376.

Explain Working Capital Ratio
Where is LGVN most successful ?
Working Capital Ratio LGVN on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 149
Healthcare Sector # 244
Within the Market # 376


TTM Working Capital Ratio Statistics
High Average Low
11.82 10.99 9.54
(Mar 31 2022)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Syndax Pharmaceuticals Inc   17.19 $ 357.631  Millions$ 20.803  Millions
Kinnate Biopharma Inc   17.02 $ 261.175  Millions$ 15.343  Millions
Cerevel Therapeutics Holdings Inc   16.64 $ 998.658  Millions$ 60.020  Millions
Adicet Bio Inc   16.59 $ 285.737  Millions$ 17.221  Millions
Cryoport inc   16.45 $ 610.051  Millions$ 37.076  Millions
Chimerix inc   16.44 $ 291.120  Millions$ 17.710  Millions
Rapt Therapeutics Inc   16.07 $ 197.894  Millions$ 12.316  Millions
Fulcrum Therapeutics Inc   15.49 $ 227.727  Millions$ 14.699  Millions
Crinetics Pharmaceuticals Inc   15.41 $ 378.422  Millions$ 24.556  Millions
Pds Biotechnology Corp  15.37 $ 74.411  Millions$ 4.841  Millions
Nkarta Inc   15.17 $ 400.918  Millions$ 26.425  Millions
Akero Therapeutics Inc   14.97 $ 377.946  Millions$ 25.243  Millions
Oric Pharmaceuticals Inc   14.96 $ 198.685  Millions$ 13.284  Millions
Lianbio  14.72 $ 324.238  Millions$ 22.027  Millions
Sage Therapeutics Inc   14.70 $ 1,465.104  Millions$ 99.687  Millions
Cytokinetics Incorporated  14.63 $ 884.275  Millions$ 60.440  Millions
Lumos Pharma Inc   14.38 $ 78.832  Millions$ 5.483  Millions
Verrica Pharmaceuticals Inc   14.10 $ 43.395  Millions$ 3.078  Millions
Rani Therapeutics Holdings Inc   14.02 $ 100.720  Millions$ 7.186  Millions
Pliant Therapeutics Inc   13.99 $ 365.965  Millions$ 26.161  Millions
Sensei Biotherapeutics Inc   13.95 $ 118.482  Millions$ 8.492  Millions
Histogen Inc   13.93 $ 16.338  Millions$ 1.173  Millions
Liquidia Corporation  13.81 $ 103.058  Millions$ 7.460  Millions
Annexon Inc   13.59 $ 274.777  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.50 $ 127.127  Millions$ 9.420  Millions
Aclaris Therapeutics Inc   13.49 $ 256.573  Millions$ 19.023  Millions
Xenetic Biosciences Inc   13.48 $ 14.167  Millions$ 1.051  Millions
Iveric Bio Inc   13.40 $ 329.478  Millions$ 24.588  Millions
Arcutis Biotherapeutics Inc   13.39 $ 496.719  Millions$ 37.102  Millions
Erasca Inc   13.21 $ 365.751  Millions$ 27.679  Millions

Date modified: 2022-11-16T07:45:10+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FTFT's Profile

Stock Price

FTFT's Financials

Business Description

Fundamentals

Charts & Quotes

FTFT's News

Suppliers

FTFT's Competitors

Customers & Markets

Economic Indicators

FTFT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071